Exiqon to Sell Calif. CLIA Lab to Gain 'Efficiencies,' Free Up Resources
December 17, 2009
Exiqon to Sell Calif. CLIA Lab to Gain 'Efficiencies,' Free Up Resources
The company said that as a result of the planned divestiture, it will seek partners to co-develop and commercialize its miRNA-based diagnostics.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Exiqon Sees Partnership for miRNA Dx by End of 2010
August 26, 2010 / Gene Silencing News - Exiqon to Shut Down California Lab After Reimbursement Issue Stymies Sale Talks
June 10, 2010 / Gene Silencing News - Exiqon Reaffirms Plan to Pursue miRNA Dx Only Through Partnerships, Provides Few Details on Programs
February 25, 2010 / Gene Silencing News - Asuragen Forms Collaborations to Develop FNA Version of Pancreatic Cancer miRNA Test
February 4, 2010 / Gene Silencing News - Exiqon to Divest CLIA Lab; Seeks Partners
December 17, 2009 / GenomeWeb Daily News